TI - Prognostic Impact of Immune-Related Adverse Events in Patients with Non–Small Cell Lung Cancer Treated with Second-Line Nivolumab: A Single-Center Real-World Experience
PT - Journal Article
DP - 2026
TA - EJMI
PG - 46-53
VI - 10
IP - 1
AID - 263046 [doi]
4100 - https://dx.doi.org/10.14744/ejmi.263046
SO - EURASIAN JOURNAL OF MEDICIAL INVESTIGATION,2026 10(1): 46